EPRX Key Statistics, Chart & Performance
The current stock price of EPRX is 7.18 USD. In the past month the price increased by 5.64%. In the past year, price increased by 119.4%.
EPRX Latest News, Press Relases and Analysis
EPRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.1 | 402.49B | ||
| AMGN | AMGEN INC | 15.13 | 178.22B | ||
| GILD | GILEAD SCIENCES INC | 15.11 | 153.56B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.3 | 115.85B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.32 | 81.93B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 801.85 | 54.03B | ||
| INSM | INSMED INC | N/A | 37.84B | ||
| NTRA | NATERA INC | N/A | 32.60B | ||
| BIIB | BIOGEN INC | 10.45 | 25.67B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.6 | 22.27B | ||
| INCY | INCYTE CORP | 15.55 | 19.60B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.30B |
Related stock screener links
About EPRX
Company Profile
Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. The company is headquartered in Victoria, British Columbia and currently employs 33 full-time employees. The company went IPO on 2021-03-09. The firm is focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The Company’s EP-104GI is in a Phase Ib/IIa trial, the RESOLVE trial, for the treatment of eosinophilic esophagitis (EoE). EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. The firm also completed a Phase IIb clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. In addition, the Company is developing a pipeline of later and earlier-stage long-acting formulations. Its potential pipeline indications include candidates for other inflammatory joint indications and oncology.
Company Info
EUPRAXIA PHARMACEUTICALS INC
201-2067 Cadboro Bay Rd.
Victoria BRITISH COLUMBIA CA
Employees: 33
Phone: 12505903968
EUPRAXIA PHARMACEUTICALS INC / EPRX FAQ
What does EPRX do?
Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. The company is headquartered in Victoria, British Columbia and currently employs 33 full-time employees. The company went IPO on 2021-03-09. The firm is focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The Company’s EP-104GI is in a Phase Ib/IIa trial, the RESOLVE trial, for the treatment of eosinophilic esophagitis (EoE). EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. The firm also completed a Phase IIb clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. In addition, the Company is developing a pipeline of later and earlier-stage long-acting formulations. Its potential pipeline indications include candidates for other inflammatory joint indications and oncology.
Can you provide the latest stock price for EUPRAXIA PHARMACEUTICALS INC?
The current stock price of EPRX is 7.18 USD. The price increased by 9.45% in the last trading session.
What is the dividend status of EUPRAXIA PHARMACEUTICALS INC?
EPRX does not pay a dividend.
How is the ChartMill rating for EUPRAXIA PHARMACEUTICALS INC?
EPRX has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is EUPRAXIA PHARMACEUTICALS INC (EPRX) stock traded?
EPRX stock is listed on the Nasdaq exchange.
What is EUPRAXIA PHARMACEUTICALS INC worth?
EUPRAXIA PHARMACEUTICALS INC (EPRX) has a market capitalization of 363.67M USD. This makes EPRX a Small Cap stock.
What is the ownership structure of EUPRAXIA PHARMACEUTICALS INC (EPRX)?
You can find the ownership structure of EUPRAXIA PHARMACEUTICALS INC (EPRX) on the Ownership tab.
EPRX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to EPRX. When comparing the yearly performance of all stocks, EPRX is one of the better performing stocks in the market, outperforming 94.71% of all stocks.
EPRX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to EPRX. EPRX has a great financial health rating, but its profitability evaluates not so good.
EPRX Financial Highlights
Over the last trailing twelve months EPRX reported a non-GAAP Earnings per Share(EPS) of -1.2. The EPS decreased by -6.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.81% | ||
| ROE | -32.63% | ||
| Debt/Equity | 0 |
EPRX Forecast & Estimates
10 analysts have analysed EPRX and the average price target is 9 USD. This implies a price increase of 25.33% is expected in the next year compared to the current price of 7.18.